Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Marimastat: Phase III

BBG said that the combination of marimastat and Eli Lilly’s Gemzar gemcitabine failed to show

Read the full 155 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE